Nature Medicine·6 OctOral small-molecule GLP-1RA safiglipron versus dapagliflozin in type 2 diabetes: a randomized, double-blind, active-comparator-controlled phase 3 trialTrial in peopleInterventionsPaper
Nature Medicine·30 SepOral small-molecule GLP-1 receptor agonist safiglipron in early type 2 diabetes: a randomized, double-blind, placebo-controlled trialRandomised trial in 284 peopleType 2 diabetesPaper